Insight

START Midwest team has successfully dosed the first patient in the first QTX3046 Phase I trial

Photo from The START Center for Cancer Research/LinkedIn

Jul 1, 2024, 11:57

START Midwest team has successfully dosed the first patient in the first QTX3046 Phase I trial

“We are proud to announce that the first patient in the Quanta Therapeutics QTX3046 Phase I trial has been successfully dosed at START Midwest. This study aims to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab in patients with KRAS G12D mutations. We’re also excited to share that this study is open at our START San Antonio site, highlighting our commitment to advancing cancer research across communities everywhere.

To learn more about the QTX3046 study, please visit here.”

Source:

cancer clinical trials KRAS G12D mutations OncoDaily Oncology oncology research QTX3046 Quanta Therapeutics Research START Midwest START San Antonio targeted therapies The START Center for Cancer Research

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage